Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.

Autor: Miscioscia A; Department of Neuroscience DNS, School of Medicine, University of Padua, Via Giustiniani, 5, 35128, Padua, Veneto Region, Italy. alessmiscioscia@gmail.com.; Multiple Sclerosis Centre, University Hospital of Padua, Padua, Veneto Region, Italy. alessmiscioscia@gmail.com., Puthenparampil M; Department of Neuroscience DNS, School of Medicine, University of Padua, Via Giustiniani, 5, 35128, Padua, Veneto Region, Italy.; Multiple Sclerosis Centre, University Hospital of Padua, Padua, Veneto Region, Italy., Miante S; Department of Neuroscience DNS, School of Medicine, University of Padua, Via Giustiniani, 5, 35128, Padua, Veneto Region, Italy.; Multiple Sclerosis Centre, University Hospital of Padua, Padua, Veneto Region, Italy.; Neurology Unit, Ospedale dell'Angelo, Mestre, Italy., Pengo M; Department of Neuroscience DNS, School of Medicine, University of Padua, Via Giustiniani, 5, 35128, Padua, Veneto Region, Italy.; Multiple Sclerosis Centre, University Hospital of Padua, Padua, Veneto Region, Italy.; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy., Rinaldi F; Multiple Sclerosis Centre, University Hospital of Padua, Padua, Veneto Region, Italy., Perini P; Multiple Sclerosis Centre, University Hospital of Padua, Padua, Veneto Region, Italy., Gallo P; Department of Neuroscience DNS, School of Medicine, University of Padua, Via Giustiniani, 5, 35128, Padua, Veneto Region, Italy.; Multiple Sclerosis Centre, University Hospital of Padua, Padua, Veneto Region, Italy.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2022 Oct; Vol. 269 (10), pp. 5436-5442. Date of Electronic Publication: 2022 Jun 01.
DOI: 10.1007/s00415-022-11183-y
Abstrakt: Background: Ocrelizumab was found to decrease brain atrophy rate in primary progressive multiple sclerosis (PPMS), but no data are currently available on the effect of ocrelizumab on retinal layer thicknesses in the PPMS population.
Objective: To assess retinal layer changes in ocrelizumab-treated PPMS and test their possible application as biomarkers of therapy response.
Methods: 36 PPMS patients, treated with ocrelizumab for at least 6 months, and 39 sex- and age-matched healthy controls (HC) were included in a blind, longitudinal study. Spectrum-domain optical coherence tomography (SD-OCT) was performed at study entry (T0) and after 6 (T6) and 12 months (T12). At month 24 (T24), patients were divided into responders (no evidence of 1-year confirmed disability progression, 1y-CDP) and non-responders (evidence of 1y-CDP).
Results: At T24, 23/36 (64%) patients were considered responders and 13/36 (36%) non-responders. At T0, peripapillary retinal nerve fiber layer (pRNFL) thickness, macular ganglion cell-inner plexiform layer (GCIPL) and inner retinal layer (IRL) volume were significantly lower in PPMS compared to HC (p = 0.001 for all comparisons). At T6 and T12, non-responders significantly differed in the inner nuclear layer (INL) thinning rate compared to responders (p = 0.005 at both time-points).
Conclusions: Ocrelizumab significantly slows down INL thinning rate in PPMS responders. The longitudinal analysis of retina layer changes by means of OCT may be a promising prognostic test, and merits further investigations.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: